ClinicalTrials.gg
RecruitingNCT07643766Updated Aug 6, 2026

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of ENV-294 and Placebo in Atopic Dermatitis, sponsored by Enveda Therapeutics. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Enveda Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
171st of 544
200 · median 96
Started
2026
with 28 others
Phase 2
202 of 639
18 open now
Primary completion
2027-12
later than 68 of 115 live
Registered
626th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 171st largest by planned enrollment of the 544 interventional ones that give a count, is one of 29 that started in 2026, is one of 202 in phase 2, reaches primary completion later than 68 of the 115 other live ones, and was the 626th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive study treatment, and complete scheduled assessments of disease activity, symptoms, quality of life, safety, pharmacokinetics, and biomarker responses.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to participate in this study all participants must:

  1. Be at least 18 years of age at the time of signing the ICF.
  2. Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to Screening.
  3. Have a history of inadequate response or intolerance to topical or other topical treatments for AD within 6 months before Screening and/or inadequate response to a systemic therapy within 12 months before Screening.
  4. Have moderate-to-severe AD, at Screening and Baseline, as defined by the following criteria:

    1. A vIGA score of 3 (moderate) or 4 (severe)
    2. EASI score of ≥16
    3. Body surface area involvement of ≥10%
  5. Have PP-NRS score ≥4 Screening and Baseline - the baseline score refers to a weekly average.
  6. Use a bland emollient daily for at least 1 week prior to Day 1 and agree to continue using that same emollient daily at the same frequency (minimally, once daily) throughout the study.
  7. Participants of (male and female participants) must practice effective methods of as per protocol.

Exclusion criteria

Exclusion Criteria:

Participants are excluded if they:

  1. Have any medical condition or physical/laboratory//vital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
  2. Have clinically significant abnormalities in any of the clinical laboratory evaluations at Screening or Baseline as determined by the Investigator.
  3. Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response as determined by the investigator.
  4. Have an ongoing clinically significant skin infection or is receiving treatment for infection that may interfere with assessment of AD as determined by the investigator.
  5. Are pregnant or breastfeeding or are planning to become pregnant during the duration of the study and for 90 days after the last administration of study drug.
  6. Are taking or have taken any prespecified prohibited therapies within a specific timeframe as determined by the Investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    ENV-294 Treatment Arm (Dose 1)

    Drug: ENV-294

  • Experimental
    ENV-294 Treatment Arm (Dose 2)

    Drug: ENV-294

  • Experimental
    ENV-294 Treatment Arm (Dose 3)

    Drug: ENV-294

  • Placebo comparator
    Placebo Arm

    Other: Placebo

Interventions

  • ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

  • OtherPlacebo

    Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

06

What researchers measure

Primary outcomes

  1. Percent change in Eczema Area and Severity Index (EASI) score

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    Time frame: Baseline to Week 12 and Week 16

  2. EASI-75 Response

    Proportion of participants with at least 75% reduction from Baseline in EASI score

    Time frame: Baseline to Week 12

  3. vIGA Response

    Proportion of participants who achieve a ≥2-point reduction from Baseline in validated Global Investigator Assessment (vIGA) score and a score of 0 or 1.

    Time frame: Baseline to Week 12

  4. Percent change in Scoring Atopic Dermatitis (SCORAD)

    Time frame: Baseline to Week 12

  5. Patient-Reported Outcomes

    Change in Patient Oriented Eczema Measure (POEM)

    Time frame: Baseline to Week 12

  6. Patient-Reported Outcomes

    Peak Pruritus Numerical Rating Scale (PP-NRS): proportion of participants who achieve weekly mean decrease from Baseline of ≥4 points

    Time frame: Baseline to Week 12

07

Study locations

9 of 9 sites recruiting
  • Enveda Investigative Site
    Encinitas, California 92024, United States
    Recruiting
  • Enveda Investigative Site
    Los Angeles, California 90045, United States
    Recruiting
  • Enveda Investigative Site
    Northridge, California 91325, United States
    Recruiting
  • Enveda Investigative Site
    Boca Raton, Florida 33486, United States
    Recruiting
  • Enveda Investigative Site
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Enveda Investigative Site
    Plainfield, Indiana 46168, United States
    Recruiting
  • Enveda Investigative Site
    Dallas, Texas 75230, United States
    Recruiting
  • Enveda Investigative Site
    San Antonio, Texas 78213, United States
    Recruiting
  • Enveda Investigative Site
    Sugar Land, Texas 77479, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 18 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2026
First posted
Jun 12, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Dec 2027
CompletionEst.
May 2028
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07643766
Lead sponsor
Enveda Therapeutics
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 29, 2026
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Aug 6, 2026

Study contacts

Clinical Operations
Contact
env-294.clinicaltrials@enveda.com
Gurpreet Ahluwalia, PhD
study director · Enveda Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENV-294

Start the discussion